Archive · 19 Dec 2025
Cipla and Pfizer Partner for Exclusive Marketing in India
Cipla and Pfizer India have teamed up to make some of Pfizer’s popular medicines more available across India.
Cipla will be responsible for marketing and distributing these medicines, while Pfizer will continue to make them.
The medicines include cough syrups, pain relievers, and antibiotics.
This partnership is expected to last five years and will help more people get access to these important treatments.
Cipla has also recently partnered with another company, Eli Lilly, to distribute a weight-loss drug in India.
Cipla and Pfizer India have partnered for exclusive marketing and distribution of four Pfizer brands in India.
The brands include Corex Dx, Corex LS, Dolonex, Neksium, and Dalacin C.
Cipla will market and distribute these medicines, while Pfizer will manufacture and supply them.
The partnership aims to increase the reach of Pfizer’s top medicines using Cipla’s extensive distribution network.
The partnership is expected to last five years, with financial terms not disclosed.
- Who
- Cipla and Pfizer India
- What
- Partnership for exclusive marketing and distribution of four Pfizer brands in India
- When
- Announced on Friday (specific date not mentioned)
- Where
- India
- Why
- To increase the reach of Pfizer’s top medicines using Cipla’s extensive distribution network
- Companies Involved
- Cipla and Pfizer India
- Brands Involved
- Corex Dx, Corex LS, Dolonex, Neksium, Dalacin C
- Partnership Duration
- 5 years
- Cipla's Role
- Exclusive marketing and distribution
- Pfizer's Role
- Manufacturing and supply